Outcomes in Transthyretin Amyloid Cardiomyopathy Examined

Transthyretin amyloid cardiomyopathy (ATTR-CM) is one of many types of systemic amyloidosis and is an underrecognized cause of heart failure in older adults.¹ Due to improvements in diagnostics such as nuclear cardiac imaging, more patients are being screened for and diagnosed with ATTR-CM.² However, treatments are limited, with only 2 FDA approved therapies available: tafamidis (Vyndamax) and tafamidis meglumine (Vyndaqel),³ with additional pharmacotherapies, such as acoramidis, being evaluated in clinical research.

In data presented at the Heart Failure Society of America 2024 Annual Meeting, scheduled to take place in Atlanta, Georgia from September 27 to September 30, researchers shared their findings across a variety of topics related to ATTR-CM treatment, comorbidities, and clinical outcomes.

Click here for more coverage of the Heart Failure Society of America 2024 Annual Meeting.

References

1. Ruberg FL, Grogan M, hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872-2891. doi:10/1016/j.jacc.2019.04.003

2. Jain A, Zahra F. Transthyretin amyloid cardiomyopathy (ATTR-CM). In: StatPearls [Internet]. Updated April 27, 2023. Accessed September 30, 2024. https://www.ncbi.nlm.nih.gov/books/NBK574531

3. Roberts JR, Lan ML, Frank VMF. Transthyretin-related amyloidosis treatment and management. Medscape. Updated March 27, 2024. Accessed September 30, 2024. https://emedicine.medscape.com/article/335301-treatment#d1

4. Sawhney A. Acoramidis for the treatment of amyloid cardiomyopathy: a meta-analysis of randomised controlled trials. Presented at: Heart Failure Society of America Annual Scientific Meeting 2024; September 27-30, 2024; Atlanta, GA. Poster 203.

5. Dasgupta N, Poulsen SH, Emdin M, et al. Contemporary oral medication usage and frequency in patients with transthyretin cardiac amyloidosis. Presented at: Heart Failure Society of America Annual Scientific Meeting 2024; September 27-30, 2024; Atlanta, GA. Poster 311.

6. Alexander KM, Dasgupta NR, Mathisen J, et al. Temporal trends in the incidence and prevalence of transthyretin amyloid cardiomyopathy in the USA: An Observational Database Study. Presented at: Heart Failure Society of America Annual Scientific Meeting 2024; September 27-30, 2024; Atlanta, GA. Poster 201.

7. De Los Santos J, Teruya S, Smiley D, Maurer M. Impact of anemia on mortality and morbidity in transthyretin cardiomyopathy: a retrospective cohort study from a single center. Presented at: Heart Failure Society of America Annual Scientific Meeting 2024; September 27-30, 2024; Atlanta, GA. Poster 306.

8. Fontana M, Kumar V, Sheridan P, et al. Descriptive analysis of unmet need in a contemporary cohort of tafamidis-treated transthyretin amyloid cardiomyopathy patients. Presented at: Heart Failure Society of America Annual Scientific Meeting 2024; September 27-30, 2024; Atlanta, GA. Poster 339.

9. Batra S, Patel H, Govi A, Panjrath G. Mortality among older transthyretin amyloid cardiomyopathy patients on tafamidis . Presented at: Heart Failure Society of America Annual Scientific Meeting 2024; September 27-30, 2024; Atlanta, GA. Poster 359.

10. Parcha V, Josey GC, Saleh A, Clarkson SA. Association of sodium-glucose co-transporter 2 inhibitors use on clinical outcomes in patients with wild-type transthyretin amyloid cardiomyopathy: a retrospective cohort study. Presented at: Heart Failure Society of America Annual Scientific Meeting 2024; September 27-30, 2024; Atlanta, GA. Poster 20.